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ABSTRACT
Objective: To assess whether clozapine is likely to be more
cost-effective than other second-generation antipsychotics
(SGAs) in people with schizophrenia.
Methods: An integrated clinical and economic multicenter,
rater-blind, randomized controlled trial (RCT) compared
clozapine to the class of other SGAs, using the perspectives of
the National Health Service, social support services, and
patients. The practice setting was secondary and primary care
in the United Kingdom; patients were followed for 1 year.
Incremental cost-effectiveness ratios (ICERs), net beneﬁt sta-
tistics, and cost acceptability curves were estimated.
Results: The ICER for clozapine was £33,240 per quality-
adjusted life-year (QALY) (range £23,000–70,000 for the
sensitivity analyses). The proportion of simulations when
clozapine was more cost-effective than other SGAs reached
50% if decision-makers are prepared to pay £30,000 to
£35,000 per QALY. This is at the top of the range of accept-
able willingness-to-pay values per QALY implied by deci-
sions taken by the National Institute for Health and Clinical
Excellence (NICE).
Conclusions: This study adds to a limited body of evidence
comparing clozapine to other SGAs and is the ﬁrst eco-
nomic and clinical RCT to compare clozapine to the class
of other SGAs using the lower cost of generic clozapine and
a pragmatic trial design. Policy decisions by the NICE
suggest that additional reasons would be needed to accept
clozapine as effective and efﬁcient if it had a high pro-
bability of having ICERs more than £35,000 per QALY.
The results and limitations of the analysis suggest that
there is still a need for further economic evaluation of
clozapine.
Keywords: antipsychotics, costs, psychosis, QALY.
Introduction
Recent mental health policy in England speciﬁes that
the delivery of care to people with psychosis should
include early intervention services, assertive outreach
services, and home treatment teams. Psychosocial
interventions have been a key part of the management
of schizophrenia since the 1970s. Although psycho-
logical treatments have been shown to be effective
when added to routine care and drug treatment, their
provision in the UK National Health Service (NHS) is
scarce [1]. The beneﬁts of antipsychotic medication in
treating acute psychotic episodes and reducing the risk
of relapse in the community are widely accepted and
documented [2,3]. Within the ﬁrst 5 to 10 years of
drug treatment, people with schizophrenia are up to
three times more likely to relapse if their antipsychotic
medication is stopped.
The older, ﬁrst generation of conventional antipsy-
chotics (FGAs) has several critical limitations, which
include unsatisfactory response in 20% to 25% of
people with schizophrenia, limited effect on the nega-
tive symptoms of the condition, and a range of poten-
tially severe unwanted effects [4,5].
The newer, second generation of “atypical” antip-
sychotics (SGAs) include clozapine, risperidone, sertin-
dole, olanzapine, quetiapine, ziprasidone, zotepine,
and amisulpride. The SGAs are a heterogeneous group
of drugs in respect of their pharmacology, side-effect
proﬁles, and efﬁcacy. Meta-analysis and clinical trial
evidence suggests that SGAs are associated with im-
proved tolerability in terms of side effects and sub-
jective experience [6–12].
There is some evidence that clozapine and other
SGAs are more effective and cost-effective than FGAs
for people who demonstrate treatment resistance or
intolerance to previous therapy [13–49]. The UK
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(NICE) suggests that for people with treatment-
resistant schizophrenia (TRS), clozapine should be
introduced at the earliest opportunity [50]. TRS is
deﬁned as a lack of satisfactory clinical improvement
after the sequential use of two or more antipsychotics
at the recommended doses for 6 to 8 weeks. At least
one of the antipsychotics should be an atypical.
Evidence about the comparative cost-effectiveness
of clozapine compared to other SGAs is limited and
uncertain. Some analyses indicate clozapine may be
more effective and less expensive, and others indicate
clozapine may be more effective and more expensive
[13,51]. A systematic review [52] concluded that trials
with sufﬁcient power, and longer duration, are needed
to assess the relative cost-effectiveness of clozapine and
other SGAs. Until recently, the costs of clozapine were
relatively high compared to other SGAs. Depending on
dosage, the costs of clozapine were approximately
£2500 per person per year, compared to £1400 per
person per year for risperidone, olanzapine, and que-
tiapine. The advent of generic clozapine in the United
Kingdom triggered a fall in the costs of clozapine to
around half the price before 2004. However, clozapine
often incurs additional costs for hospital inpatient care
to ensure that the patients are adequately monitored
for agranulocytosis.
Methods
Aims and Objectives
The aim of the economic evaluation was to assess
whether there were differences in the relative cost-
effectiveness of clozapine compared to other SGAs to
address the research question: Is clozapine likely to be
more cost-effective than other SGAs in a population
with narrowly deﬁned TRS?
Approach
The economic evaluation was part of a multicenter,
rater-blind, randomized controlled trial (RCT) of
clozapine versus the class of other SGAs, in people
with schizophrenia unresponsive to or intolerant to
current treatment. Clozapine (due to licensing restric-
tions) could not be used as ﬁrst- or second-line therapy
and the use of FGAs as second- or third-line therapy is
now less common in the United Kingdom with the
advent of other newer SGAs. The newer SGAs as a
class were perceived to be superior to FGAs, and cloza-
pine superior to both other SGAs and FGAs. A key
issue for the NHS was the relative effectiveness and
cost-effectiveness of clozapine versus other SGAs in
routine practice.
Key design elements of the trial were that, entry was
deﬁned by the clinician making a decision to change
drugmanagement. Broad inclusion criteriawere used to
approximate normal clinical practice. Patients recruited
into the trial were randomly allocated to switch therapy
to clozapine or to switch therapy to a nonclozapine
SGA. For participants allocated to the nonclozapine
SGA arm of the trial, clinicians and patients chose
which drug to use within the class, reﬂecting normal
clinical practice. There was nonintensive follow-up
with a small number of primary outcomes over a sched-
uled 12-month follow-up. This allowed long enough to
observe changes in primary and secondary outcomes,
including side effects and switches from the allocated
medication, while being feasible to implement and
provide timely data to clinical and policy decision-
makers. The 12-month follow-up period is longer than
that used in most clinical trials of clozapine, and similar
to recent randomized controlled economic and clinical
trials of clozapine [40,53,54]. The primary outcome
was the Quality of Life Scale (QLS). Secondary out-
comes included measures of symptoms (Positive and
Negative Syndrome Scale [PANSS], Global Assessment
of Functioning Scale [GAF]) and incremental cost-
effectiveness ratios (ICERs). The QLS score was used to
determine the sample size. It was estimated that 60
patients in each groupwould allow 85%power to show
a difference in change scores of 10 points (i.e., mean
12-month scores of 35 vs. 45). Alternatively, 70 in each
arm would be needed for 90% power. Estimating a
15% dropout rate at 12 months, it was concluded that
138 patients were required in total.
The main conclusion from the clinical analysis was
that there was no statistically signiﬁcant advantage to
clozapine in terms of quality of life as measured by the
QLS. Nevertheless, there was a statistically signiﬁcant
advantage to clozapine in terms of symptom improve-
ment (as measured by the PANSS) over the 1-year
follow-up period [53].
The economic evaluation used the perspectives of
the NHS, social support services and patients for the
primary analysis (the main stakeholders), approximat-
ing a societal perspective. The practice setting was
secondary and primary care in the United Kingdom
and patients were followed up from the day of ran-
domization to the end of scheduled follow-up at
1 year. Discounting of future costs and outcomes was
not necessary for this time frame. Economic data were
collected for all the patients enrolled in the clinical
trial to estimate resource use, costs, and utilities. The
primary measure for the economic analysis was the
cost per quality-adjusted life-year (QALY) gained
by clozapine. Cost-effectiveness acceptability analysis
(CEAA) was used to assess the level of uncertainty in
the data. Sensitivity analysis was used to assess the
impact of structural uncertainty due to design and
analysis decisions.
Quality-Adjusted Life-Years
Health status was measured by the Euroqol question-
naire at 12 weeks, 26 weeks, and 52 weeks from
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baseline randomization. The Euroqol is a validated
generic health status measure, used in national health
surveys in the United Kingdom and in clinical trials
in mental health, covering ﬁve domains (mobility,
self-care, usual activity, pain/distress, and anxiety/
depression). The health status proﬁles were converted
to utility values using the published utility tariffs for
the Euroqol [55]. The QALYs were estimated as:
QALY U U t ti i i i= +( )[ ] × −( )+ +∑ 1 12
where U = utility value and t = number of days
between assessments.
QALYs and the Euroqol have not been widely used
in economic evaluations of treatment for schizophre-
nia. Nevertheless, the need to demonstrate value for
money of interventions combined with international
standards and local guidelines for the design of eco-
nomic evaluations support the use of QALYs as the
health measure for economic analyses [56,57]. There is
evidence that the Euroqol has acceptable validity for
patients with schizophrenia in European countries
[58,59].
Direct Costs
Only direct costs of services used to produce care were
included in the economic analysis [56,57]. The main
types of resource use were hospital inpatient and out-
patient services, primary and community care services,
and prescribed medications. Data on the use of psychi-
atric and nonpsychiatric hospital care and medication
were obtained by case note review for each trial par-
ticipant. Patients also completed an economic ques-
tionnaire at each assessment to identify whether they
had used any other hospital, primary or community
care services since the last assessment. If additional
services had been used, this information was used to
review hospital, primary and community care records
to identify the frequency and intensity of the additional
service use.
Information about accommodation, use of the
criminal justice system, and use of informal care was
excluded from the estimate of the direct costs of care.
It was anticipated that, over a 12-month period,
accommodation and use of informal care were deter-
mined by organizational systems and social settings
more than the choice of antipsychotic medication. If
the groups were unbalanced on these variables at
baseline, this could introduce bias to the analysis.
Additionally, the range of data collected meant that
it was only possible to collect information about
the use of the criminal justice system and informal
care from patient report. There were concerns that
use of these services may be inconsistently and in-
accurately reported by patients. It was not possible to
validate the use of criminal justice services from
other sources. Assessment with informal carers
was attempted, to validate the use of their time
and services. However, it proved difﬁcult to both
identify carers and obtain informed consent from
both patients and the carers to conduct the
interviews.
The direct costs were measured as resource use mul-
tiplied by the unit cost or price of the resource item.
The mean cost (standard deviation) of events was esti-
mated from the clinical trial data and published
national unit cost data. The price year was 2005–06.
Unit costs were standardized to this year using an
appropriate hospital and community health price
index [60].
Hospital Trust Financial returns data [61] indi-
cated a high degree of variability of the unit costs of
the hospitals and trial centers included in the evalu-
ation. National average unit cost data were used to
control for the differences in unit costs between care
settings. Detailed national unit cost data published by
the UK Department of Health were used to estimate
the costs of psychiatric inpatient and outpatient
hospital care, by type of ward or outpatient visit.
Detailed reference cost data were not available to
cost other categories of service use. The Hospital
Trust Financial returns data [61] were used to esti-
mate the cost of nonpsychiatric hospital care by type
of ward or admitting specialty.
For each study participant, detailed information
about medication (dose, duration, and route of admin-
istration) was used to calculate a daily cost for oral
medication and cost per injection or dose for depot
and topical or use as required medicines. The daily cost
was estimated from the British National Formulary
[62]. This daily cost was multiplied by the reported
duration for courses of treatment completed within the
study period and by the length of the study period for
courses of treatment that were ongoing. The cost of
medicines did not include the costs of dispensing or
administration. It was assumed that these costs were
included in the costs of hospital inpatient and outpa-
tient care and/or primary and community care. Cloz-
aril and Denzapine comprise 75% to 80% of clozapine
prescribed in secondary care and 95% of clozapine
prescribed in primary care in England (Personal com-
munication with pharmaceutical companies, local pro-
viders [63]), and were used to estimate the cost of
clozapine for the primary analysis. The published price
of Clozaril and Denzapine is the same at £0.88 per
100 mg tablet [62]. Zaponex, an alternative formula-
tion was lower cost (£0.59 per 100 mg tablet) and
used for the sensitivity analysis. All three formu-
lations included the costs of monitoring systems for
agranulocytosis.
The unit costs of primary and community-based
care services were derived from the costs of health and
social care published by the Personal Social Services
Research Unit, University of Kent [60].
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Incremental Cost-Effectiveness Ratios
Costs and QALYs were adjusted to control for the
effect of potentially confounding baseline variables.
The baseline covariates were selected by ﬁrst deﬁning
potential determinants of costs and QALYs. These
were evaluated with correlation (continuous) and
anova (categorical) analyses to identify associations
between baseline variables and costs and QALYs. The
signiﬁcance of these variables was tested using regres-
sion analyses. Variables with a P-value of 0.05 or less
were included as covariates to estimate adjusted means
for total cost per person, total QALY per person and to
conduct the CEAA. The baseline covariates were used
to adjust the primary and all sensitivity analyses.
The primary measure for the economic analysis
was the ICER. Bootstrapping was used to derive esti-
mates of imputed cost and QALY values, the cost-
effectiveness plane of the ICER, net beneﬁt statistics,
and cost acceptability curves to determine the prob-
ability that clozapine was cost-effective compared to
other SGAs [64,65]. The net beneﬁt and cost accept-
ability analysis used a £0 to £35,000 range of cost/
QALY threshold values, in increments of £1000 to
estimate mean net beneﬁt and the probability that an
intervention was cost-effective.
Data Manipulation and Missing Data
All missing resource use data were treated as missing at
random. This was based on the assumptions that the
level of missing data for psychiatric hospital care (the
key cost component) was minimal and the use of other
services was determined by external factors (e.g., avail-
ability and organization of services, and a patient’s
living situation and accommodation) rather than
choice of antipsychotic. Multiple imputation (pro-
pensity score method) was used to impute values for
missing costs, by category of resource use. The impu-
tation model included study period (baseline to week
12, week 13 to week 26, and week 27 to week 52) and
treatment allocation group as ﬁxed covariates.
Missing health status data for patients who com-
pleted scheduled follow-up but had missing observa-
tions were imputed by linear interpolation (value of
previous period plus value of next period divided by 2)
if observations of either side of the missing item were
available. This was based on the assumption that
utility values and time for one assessment period were
linearly correlated with those of the previous and
future assessment periods. If data for the baseline
assessment were missing, but all subsequent assess-
ments were completed, then the baseline value was
imputed as the ﬁrst observation carried backwards.
Linear interpolation was not used if patients did not
complete follow-up. Any patients with one or more
missing observations at the end of the period were
treated as censored cases. For patients with censored
data due to withdrawal or loss to follow-up, missing
utility values and time between assessments were
imputed from the mean values of those who completed
scheduled follow-up or died, for each treatment
allocation. Cox regression was used to estimate the
survival function and probability of survival at each
assessment point, using patient status (alive, dead, or
withdrawn) and treatment allocation. The QALYs for
this group were estimated as:
QALY U U S S t tC i i i i i i= +( )[ ] +( )[ ] −( )+ + +∑ 1 1 12 2
where U = utility value, S = probability of survival,
and t = number of days between assessments.
The economic data were manipulated in SPSS
version 11.5 (SPSS Inc., Chicago, IL) [66]. Multiple
imputation was conducted in using SOLAS for missing
data analysis, version 3.2 (Statistical Solutions Ltd,
Cork, Ireland) [67]. Statistical and bootstrap analy-
ses were conducted using Intercooled STATA v.9.2
(StataCorp LP, College Station, TX).
Sensitivity Analyses
Several assumptions were required to deal with
missing observations and censored cases, for both
QALYs and costs. A complete case analysis was
included to assess the impact of imputing missing data.
The impact of lower unit costs for clozapine, alterna-
tive sources of unit cost data [60,61], and adjustment
for outpatient initiation of the allocated drug therapy
was also tested in the sensitivity analysis. The latter
was considered important because there was a licens-
ing requirement for inpatient admission to commence
clozapine. In 2002, this licensing restriction for inpa-
tient initiation of clozapine was relaxed in the United
Kingdom and some Trusts initiated a daycase initiation
policy for clozapine during the course of the trial. If an
inpatient admission started after randomization and
before or on the ﬁrst day of the allocated drug treat-
ment, it was assumed that initiation of drug therapy
was a primary reason for admission. If the admission
started before randomization or after the day of the
ﬁrst dose of the allocated drug treatment, it was
assumed that initiation of drug therapy was not a
primary reason for admission. Reason for admission
was included as a covariate for this sensitivity analysis.
All the sensitivity analyses were also adjusted
for the baseline covariates included in the primary
analysis.
Results
All patients allocated to therapy in the clinical trial
were included in the economic analysis (n = 67 cloza-
pine; n = 69 other SGAs). Scheduled follow-up was
12 months and the average follow-up was 12 months
for clozapine and 11.5 months for patients allocated to
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other SGAs. Sixty patients in the clozapine group com-
pleted the 12-month assessment (89%) compared to
58 people in the other SGA group (84%). Overall,
54% of those randomized to clozapine and 56% of
those randomized to a new atypical remained in the
randomized class at week 52. A number of baseline
characteristics were identiﬁed as potential determi-
nants of costs and QALYs. These included health
status (Euroqol utility values, QLS), severity of symp-
toms (PANSS, GAF), duration of psychosis, age (at
baseline and onset of ﬁrst episode), costs for the
3 months before entry to the trial (as an indicator of
severity and potential reliance on service use), avail-
ability of services by location, whether a patient was
an inpatient at baseline, and whether a patient was
detained as a hospital inpatient under an informal or
formal section of the Mental Health Act. Of these,
baseline utility and whether a patient was detained
under a section of the Mental Health Act were statis-
tically signiﬁcant predictors of QALYs. Severity of
symptoms (GAF), previous costs, location, whether a
participant was an inpatient at baseline, and whether a
patient was detained under a section of the Mental
Health Act were statistically signiﬁcant predictors of
costs (P < 0.05). Table 1 shows these baseline charac-
teristics by treatment allocation.
Table 2 shows the unadjusted health status, utility,
and QALYs for 12 months. These data include
imputed values but are not adjusted for differences in
baseline characteristics. The unadjusted comparison of
QALYs suggests that there may be a slight advantage
for clozapine.
The unadjusted complete case analysis of costs indi-
cates that there was a trend for higher costs in the
Table 1 Characteristics of patients at baseline assessment
Euroqol health status index
Clozapine
(N = 67) Other SGAs (N = 69)
n % n %
Mobility
I have no problems in walking about 46 69 40 58
I have some problems in walking about 21 31 27 39
I am conﬁned to bed 0 0 1 1
Self-care
I have no problems with self-care 48 72 48 70
I have some problems with self-care 18 27 20 29
I am unable to wash or dress myself 1 1 0 0
Usual activities
I have no problems with performing my usual activities 37 55 27 39
I have some problems with performing my usual activities 23 34 31 45
I am unable to perform my usual activities 7 10 10 14
Pain/discomfort
I have no pain or discomfort 33 49 30 43
I have moderate pain or discomfort 30 45 27 39
I have extreme pain or discomfort 4 6 11 16
Anxiety/depression
I am not anxious or depressed 20 30 25 36
I am moderately anxious or depressed 41 61 27 39
I am extremely anxious or depressed 6 9 16 23
Utility (mean, SD) 0.65 0.26 0.57 0.38
GAF (mean, SD) 37 14 35 13
Costs for 3 months prebaseline (£) (mean, SD) 7691 8774 6788 8355
Patient status at baseline
Inpatient 41 61 35 51
Day patient/outpatient 26 39 34 39
Detained as an inpatient under a section of the Mental Health Act
Informal 46 69 52 75
Formal 10 15 8 10
Forensic 7 10 7 10
Location
Center 1, Greater Manchester 17 25 20 29
Center 2, Nottingham 23 34 23 33
Center 3, Southeast London 11 16 11 16
Center 4, Northwest London 13 19 14 20
Center 5, Cambridge & Peterborough 3 4 1 1
Initial SGA chosen within allocated group
Quetiapine 0 0 20 29
Risperidone 0 0 7 10
Amisulpride 0 0 8 12
Olanzapine 0 0 30 44
Other 0 0 4 6
Clozapine 67 100 0 0
GAF, Global Assessment of Functioning Scale; SGA, second-generation antipsychotic.
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clozapine group for all but the ﬁnal assessment period
(Table 3). This difference was due to lower psychiatric
hospital inpatient costs for the clozapine group in the
ﬁnal 6-month assessment period. Nevertheless, the
number of patients with complete cost data was lower
in the ﬁnal assessment period than previous assessment
periods and comprised 67% of patients in the clozap-
ine group and 64% of patients allocated to other
SGAs. Using available data, 60 (89%) of patients in
the clozapine group and 64 (93%) of patients allocated
to other SGAs had psychiatric inpatient data for the
ﬁnal 6-month follow-up period. The imputed data set
suggests that psychiatric hospital inpatient costs and
total costs were higher for clozapine than for other
SGAs in all assessment periods.
There appeared to be variation in costs by location,
whether a patient was an inpatient at baseline and
whether the patient was admitted to hospital under an
informal or formal section order (Table 4).
The bootstrapped estimates of cost-effectiveness
illustrate the level of uncertainty in the data. The cost-
effectiveness plane in Figure 1 indicates that the major-
ity of bootstrapped pairs of costs and QALYS show an
incremental QALY beneﬁt for clozapine at higher or
lower cost than other SGAs. However, a proportion of
the bootstrapped pairs indicate that clozapine is asso-
ciated with lower QALYS and higher costs than other
SGAs.
The adjusted primary and sensitivity analyses
suggest that clozapine may be associated with higher
Table 2 Health status, days follow-up and QALYs, 1-year, unadjusted data
Euroqol health status index
Clozapine Other SGAs
n % n %
Mobility
I have no problems in walking about 48 72 48 70
I have some problems in walking about 11 16 11 16
I am conﬁned to bed 0 0 0 0
Missing 8 12 10 14
Self-care 51 76 48 70
I have no problems with self-care 8 12 11 16
I have some problems with self-care 0 0 0 0
I am unable to wash or dress myself 8 12 10 14
Missing 41 61 31 45
Usual activities 16 24 25 36
I have no problems with performing my usual activities 2 3 3 4
I have some problems with performing my usual activities 8 12 10 14
I am unable to perform my usual activities 41 61 34 49
Missing 17 25 24 35
Pain/discomfort 1 1 1 1
I have no pain or discomfort 8 12 10 14
I have moderate pain or discomfort 26 39 24 35
I have extreme pain or discomfort 31 46 32 46
Missing 1 1 3 4
Anxiety/depression 9 13 10 14
I am not anxious or depressed 48 72 48 70
I am moderately anxious or depressed 11 16 11 16
I am extremely anxious or depressed 0 0 0 0
Missing 8 12 10 14
Mean SD Mean SD
Days follow-up (n = 65 clozapine, 69 other SGAs) 360 83 353 97
Utility* 0.81 0.18 0.74 0.22
QALYs* 0.74 0.20 0.68 0.22
QALYs by location
Center 1, Greater Manchester (n = 17 clozapine, 20 other SGAs) 0.66 0.22 0.60 0.20
Center 2, Nottingham (n = 23 clozapine, 23 other SGAs) 0.74 0.12 0.70 0.23
Center 3, Southeast London (n = 11 clozapine, 11 other SGAs) 0.76 0.29 0.67 0.25
Center 4, Northwest London (n = 13 clozapine, 14 other SGAs) 0.86 0.11 0.74 0.21
Center 5, Cambridge & Peterborough (n = 3 clozapine, 1 other SGAs) 0.62 0.38 0.93 —
QALYs by patient status at baseline
Inpatient (n = 41 clozapine, 35 other SGAs) 0.77 0.22 0.67 0.21
Daypatient (n = 2 clozapine, 2 other SGAs) 0.80 0.02 0.50 0.44
Outpatient (n = 24 clozapine, 31 other SGAs) 0.70 0.17 0.70 0.22
Not known (n = 1 clozapine, 1 other SGAs) 0.47 NA
QALYs by detained as an inpatient under a section of the Mental Health Act
Informal (n = 46 clozapine, 52 other SGAs) 0.72 0.18 0.67 0.24
Formal S2 (n = 0 clozapine, 1 other SGAs) 1.00 —
Formal S3 (n = 10 clozapine, 7 other SGAs) 0.86 0.11 0.60 0.14
Forensic (n = 7 clozapine, 7 other SGAs) 0.89 0.14 0.76 0.12
Not admitted under section (n = 2 clozapine, 2 other SGAs) 0.43 0.36 0.82 —
Not known (n = 2 clozapine, 1 other SGAs) 0.53 0.49 0.47 —
*Includes imputed values for missing observations and censored cases, n = 67 clozapine, n = 69 other SGAs.
NA, not applicable; QALY, quality-adjusted life-year; SGA, second-generation antipsychotic.
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net costs and higher net QALYs than other SGAs
(Table 5). This gives an ICER of £33,240 for the
primary analysis (range £23,000–70,000 for the sen-
sitivity analyses). Nevertheless, the 95% conﬁdence
intervals for both costs and QALYs cross zero, suggest-
ing that these differences were not independently sta-
tistically signiﬁcant.
In the primary analysis, the proportion of simula-
tions when clozapine was more cost-effective than
other SGAs only reached 50% when the ceiling
“willingness-to-pay” value reached a threshold of
£30,000 to £35,000 (Table 6, Fig. 2). This means that
at this level of willingness-to-pay, clozapine was more
cost-effective than other SGAs in more than 50% of
Table 3 Cost of services (£, 2005–06), complete case analysis, unadjusted data (excludes patients with missing cost data)
Study period
Psychiatric
hospital
Other
hospital Antipsychotics
Other
medicines
Community
& primary Total cost
Baseline–week 12
Clozapine
Mean 11,214 9 123 57 170 11,572
SD 8,842 39 102 89 281 8,853
n 52 52 52 52 52 52
Other SGAs
Mean 9,108 33 174 60 323 9,698
SD 10,947 166 172 81 641 10,806
n 51 51 51 51 51 51
Week 13–week 26
Clozapine
Mean 10,182 189 198 96 243 10,908
SD 12,227 718 158 140 330 12,351
n 50 50 50 50 50 50
Other SGAs
Mean 7,443 4 220 91 133 7,891
SD 11,277 16 184 145 254 11,247
n 47 47 47 47 47 47
Week 27–week 52
Clozapine
Mean 12,195 530 393 202 441 13,762
SD 20,823 3,252 304 261 852 22,243
n 44 45 45 45 45 45
Other SGAs
Mean 15,013 189 326 197 403 16,128
SD 23,833 1,213 349 252 906 23,854
n 44 44 44 44 44 44
SGA, second-generation antipsychotic.
Table 4 Annual mean cost (includes imputed values for missing observations and censored cases; £, 2005–06)
Clozapine Other SGAs
n Mean SD n Mean SD
All participants 67 33,227 34,296 69 28,323 32,798
Location
Center 1, Greater Manchester 17 18,713 12,828 20 12,938 13,653
Center 2, Nottingham 23 25,608 23,897 23 18,308 22,824
Center 3, Southeast London 11 22,169 20,525 11 30,465 22,393
Center 4, Northwest London 13 78,558 44,992 14 64,750 45,944
Center 5, Cambridge & Peterborough 3 17,987 11,345 1 32,784
Patient status at baseline
Inpatient 41 48,436 35,991 35 48,079 34,953
Daypatient 2 14,737 3,256 2 3,819 3,588
Outpatient 24 8,784 7,511 31 7,725 10,902
Not known 0 1 24,382
Admitted under section
Informal 46 22,230 20,572 52 17,257 19,670
S2 0 1 16,207
S3 10 42,488 32,783 7 52,456 36,498
Forensic 7 101,321 38,229 7 78,675 45,018
Not admitted under section 2 22,895 9,732 1 98,374
Not known 2 11,836 6,632 1 24,382
SGA, second-generation antipsychotic.
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Figure 1 Cost-effectiveness plane, primary analysis. QALY, quality-
adjusted life-year; SGA, second-generation antipsychotic.
Table 5 Incremental costs, QALYs, and cost/QALY of clozapine compared to other SGAs, adjusted for covariance* (£, 2005–06)
Analysis
Net cost of clozapine Net QALY of clozapine Cost/QALY
gainedNet cost SE† 95% CI† Net QALY SE† 95% CI†
Primary analysis, imputed cost and 1,662 3,466 -8,455–5,131 0.05 0.03 -0.02–0.11 33,240
QALY data, adjusted for covariance*
Sensitivity analysis
Imputed costs and QALYs data, unadjusted for covariance 4,904 5,753 -6,475–16,283 0.07 0.04 -0.01–0.14 70,057
Costs and QALYs for patients with complete data, adjusted
for covariance*
1,105 3,917 -8,783–6,572 0.02 0.03 -0.03–0.08 55,250
Net costs estimated with PSSRU unit costs, imputed cost
and QALY data, adjusted for covariance*
1,154 3,374 -7,768–5,459 0.05 0.03 -0.02–0.11 23,080
Net costs estimated with CIPFA unit costs, imputed cost
and QALY data, adjusted for covariance*
1,220 3,381 -7,846–5,407 0.05 0.03 -0.02–0.11 24,400
Lower cost of clozapine (£0.06/mg), imputed cost and
QALY data, adjusted for covariance*
1,618 3,459 -5,229–8,465 0.05 0.03 -0.02–0.11 32,360
Costs adjusted for inpatient admission to initiate drug,
imputed cost and QALY data, adjusted for covariance*
-92 3,658 -7,335–7,149 0.05 0.04 -0.03–0.12 NA
Costs adjusted for inpatient admission to initiate drug and
lower cost of clozapine (£0.06/mg), imputed cost and
QALY data, adjusted for covariance*
-139 3,677 -7,346–7,067 0.05 0.04 -0.03–0.12 NA
*Costs were adjusted for severity of illness as measured by the GAF scale, the costs for 3 months before baseline, location,whether patient was inpatient or outpatient at baseline
and whether the patient was admitted as an inpatient under section. QALYs were adjusted for baseline utility, costs for 3 months before baseline and whether the patient was
admitted as an inpatient under section.
†Standard error (SE) and 95% conﬁdence intervals (CIs) estimated on net costs and net QALYs.
CIPFA, Chartered Institute of Public Accountants; NA, not applicable; PSSRU, Personal Social Services Research Unit; QALY, quality-adjusted life-year; SGA, second-generation
antipsychotic.
Table 6 Net monetary beneﬁt (NMB) and probability clozapine is cost-effective
WTP
value
(£)
Primary
analysis
Low-cost
clozapine
CIPFA unit
costs
PSSRU unit
costs
Complete
case
analysis
Adjusted
inpatient
initiation
of therapy
Adjusted inpatient
initiation of therapy
and lower cost
of clozapine
Unadjusted
analysis
NMB P NMB P NMB P NMB P NMB P NMB P NMB P NMB P
1 -1403 0.35 -1336 0.35 -1037 0.38 -975 0.39 -938 0.41 339 0.54 373 0.54 0 0.19
5,000 -1179 0.37 -1115 0.37 -853 0.40 -790 0.41 -861 0.41 520 0.56 532 0.56 -4585 0.21
10,000 -955 0.39 -894 0.40 -668 0.42 -606 0.43 -784 0.42 701 0.58 690 0.58 -4257 0.23
15,000 -731 0.42 -673 0.42 -483 0.44 -421 0.45 -706 0.43 882 0.59 849 0.59 -3929 0.24
20,000 -507 0.45 -452 0.45 -299 0.46 -236 0.47 -629 0.43 1063 0.61 1008 0.60 -3601 0.26
25,000 -283 0.47 -232 0.47 -114 0.48 -52 0.49 -552 0.44 1244 0.63 1167 0.62 -3273 0.28
30,000 -59 0.49 -11 0.49 71 0.50 133 0.51 -474 0.45 1425 0.64 1325 0.63 -2945 0.30
35,000 165 0.52 210 0.52 255 0.52 318 0.53 -397 0.46 1606 0.66 1484 0.65 -2617 0.32
40,000 388 0.54 431 0.54 440 0.54 502 0.55 -320 0.47 1787 0.68 1643 0.66 -2289 0.34
45,000 612 0.57 652 0.57 625 0.56 687 0.57 -242 0.48 1968 0.69 1802 0.67 -1961 0.36
50,000 836 0.59 873 0.59 809 0.58 872 0.59 -165 0.48 2148 0.70 1960 0.69 -1633 0.39
CIPFA, Chartered Institute of Public Accountants; PSSRU, Personal Social Services Research Unit;WTP, Willingness-to-pay.
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simulations. The threshold value of £30,000 to
£35,000 is at the top of the range of acceptable
willingness-to-pay values to gain 1 QALY implied by
decisions taken by the NICE (£25,000–35,000 [68]).
The sensitivity analysis indicates that using the lower
price of clozapine does not substantively increase the
probability that clozapine is cost-effective. How-
ever, adjusting for whether initiation of the allocated
drug therapy was likely to be a primary reason for
inpatient admissions, led to net savings for clozapine
and a higher probability that the drug was cost-
effective. The complete case analysis and the analysis
unadjusted for baseline covariates suggest that cloza-
pine is not likely to be cost-effective within the range
of willingness to pay values implied by the NICE
decisions.
Discussion
In summary, the results for the primary and sensitivity
analyses suggest that clozapine was associated with
higher costs and higher QALYs than other SGAs for
the 12-month period following a change in antipsy-
chotic therapy due to intolerance or lack of response. If
fewer people are admitted as hospital inpatients to
initiate clozapine therapy, then clozapine may be
associated with lower costs and higher QALYs
than other SGAs. The cost-effectiveness acceptability
analyses suggest the probability that clozapine is cost-
effective is more than 50% if decision- and policy-
makers are willing to pay between £30,000 and
£35,000 to gain 1 QALY. The results are sensitive to
the analytical methods used. Clozapine was less likely
to be cost-effective than other SGAs if complete case
analysis was used or if the results were not adjusted for
key baseline covariates. These results were derived
from data collected as an integral part of a randomized
controlled clinical trial and represent the ﬁrst inte-
grated economic and clinical RCT to compare clozap-
ine to the class of other SGAs. The use of an RCT
strengthens the reliability and internal validity of the
data collected. Nevertheless, the analysis is subject to a
number of limitations.
First, the numbers of participants allocated to each
group was relatively small. Sequential statistical tests
of differences in costs and QALYs were not conducted.
Net beneﬁt statistics and cost-effectiveness acceptabil-
ity curves were estimated to explore the likelihood that
FGAs were more or less cost-effective than SGAs and
estimate uncertainty. The trial was powered to detect
differences in the primary clinical measure (QLS)
rather than differences in costs, QALYs, or net beneﬁt.
Post hoc sample size calculations indicate that the
power to detect statistically signiﬁcant differences in
net monetary beneﬁt (NMB) was low. If decision-
makers consider important differences in costs and
QALYS to be £1600 and 0.05, respectively, and are
prepared to pay £35,000 to gain 1 QALY, then there
was 50% power to detect statistically signiﬁcant dif-
ferences in NMB. If the minimum important differ-
ences in costs and QALYs are less or decision-makers
are prepared to pay less to gain 1 QALY, then the
power to detect statistically signiﬁcant differences in
NMB was lower. Insufﬁcient power increases the
chance of Type II errors (failing to reject the null
hypothesis of no differences between groups when a
difference does exist). Nevertheless, using a Bayesian
framework to address the hypothesis that clozapine
is cost-effective, the cost-effectiveness acceptability
analyses and curves directly address the question of
whether an intervention is likely to be cost-effective,
without hypothesis testing, and risk of a Type II error
[69,70]. The CEAA estimates the probability that an
intervention is cost-effective, given the observed data,
at different levels of willingness to pay to gain a QALY,
based on an empiric sampling distribution derived
from bootstrap samples of the original data. All the
primary and sensitivity analyses indicated that using
the observed data from this trial, clozapine was likely
to be cost-effective (probability >50%) if decision-
makers were prepared to pay £30,000 to £35,000 to
gain 1 QALY.
Second, the Euroqol was used to measure the self-
reported health status and associated utility of par-
ticipants at each assessment point. The Euroqol and
associated population utility values are validated
measures for the estimation of QALYs and for use
in schizophrenia in Europe [58,59]. However, as
generic measures they may not be sensitive to small but
important changes in health and health-related quality
of life. There were small differences in QALYs between
clozapine and alternative SGAs. The differences were
similar to those found in UK-based modeling studies
[13,14]. Analysis of the trial data indicated that the
utility values correlated with other outcome measures
baseline (QLS, Pearson 0.172, P = 0.05; PANSS,
Pearson -0.330, P < 0.000; GAF, Pearson 0.331,
P < 0.000) and at 1-year follow-up (QLS, Pearson
0.223, P = 0.01; PANSS, Pearson -0.297, P < 0.000;
GAF, Pearson 0.223, P < 0.01). Changes in health
status and in utility were also detected over the
52-week follow-up period.
Third, although the trial achieved a relatively high
level of follow-up in the context of trials of antipsy-
chotic medication, total cost data were only available
for 65% of participants. Overall, 70% of those ran-
domized to clozapine and 71% of those randomized to
a new atypical remained in the randomized class at
week 12; at week 52, this was 54% and 56%. Data to
calculate utility and QALY values were available for
77% to 88% of patients at week 52. Data on the use
of psychiatric hospital care at the 52-week follow-up
were available for most patients randomized to treat-
ment (89% clozapine vs. 93% other SGAs). Complete
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data were lower for other cost categories, the lowest
rate of follow-up being the use of primary and com-
munity care services at 72% to 77%. Nevertheless, the
use of psychiatric hospital care comprised the majority
of the total costs of care (91% clozapine vs. 92% other
SGAs). This suggests that the impact of missing data
on total cost per person due to loss of follow-up is
likely to be low. However, imputation of missing data
was conducted to estimate total QALYs and costs for
all patients in the trial, and to reduce the impact of any
bias induced by missing observations or censored data.
Sensitivity analysis tested whether the results differed
between the imputed data and complete case analyses.
The analysis using imputed data reduces the potential
for bias associated with missing data, which is parti-
cularly important in studies with multiple follow-up
points. Imputation of missing observations reduced the
cost per QALY gained by clozapine, compared to the
complete case analysis. Missing cost data were treated
as missing at random, rather than informative censor-
ing of data. This was based on the assumption that use
of services and subsequent costs was determined by a
range of factors in addition to treatment allocation,
which was supported by the analysis to identify base-
line determinants of cost. The adjusted R2 for this
analysis was 0.70, suggesting that 70% of the total
cost was determined by organizational and patient
characteristics at entry into the trial, rather than pri-
marily treatment allocation.
Because of the potentially high inﬂuence of orga-
nizational and patient characteristics on both costs
and outcomes, analysis of covariance was used to
control for the impact of factors other than treatment
allocation. Several baseline variables were identiﬁed
as statistically signiﬁcant predictors of QALYs or
costs. These variables were used to adjust the esti-
mates of mean costs and QALYs, the ICER and the
CEAA. Adjusting the estimates of costs and QALYs
for baseline characteristics reduced the incremental
cost per QALY gained by clozapine when compared
to the unadjusted comparison of clozapine and other
SGAs.
Fourth, although the analysis included a broad
range of direct costs (psychiatric and nonpsychiatric
hospital admissions, hospital outpatient, daycare and
clinic services, medication, community-based and pri-
mary care services), the costs of contacts with the
criminal justice system, use of residential accommoda-
tion, and informal care were excluded. The indirect
costs of withdrawal from paid employment were also
excluded. A descriptive analysis of these variables sug-
gests that the level of use was low and that there were
few differences in the use of these services over the
12-month period of the trial. Nevertheless, the total
costs are underestimated, which may bias the results if
there were important differences in utilization because
of the choice of antipsychotic rather than the use of
these services at baseline and the inﬂuence of organi-
zational and social factors.
The economic analysis used data from a pragmatic
RCT, designed to reﬂect practice in the United
Kingdom. The trial was conducted in ﬁve centers
that covered different geographic areas in the United
Kingdom. The trial patients were recruited from and
treated in 20 different hospitals. Most of the hospitals
were District General Hospitals rather than University
Teaching Hospitals. These factors mean that the
trial was conducted in a variety of practice settings
that reﬂect the range of routine care in the United
Kingdom. Although the costs of inpatient care and
consequently the total annual costs per person varied
by trial center, the mean (SD) length of stay per person
admitted to psychiatric hospital (67 [34] days clozap-
ine, 71 [37] days other SGAs, 69 [36] days overall) was
in the range of inpatient stays found in England
between 1999 (55 days) and 2005 (83 days). This
suggests that the cost data may be generalizable to
England overall. The validity of extrapolating the
results to alternative locations within the United
Kingdom needs to be assessed against local practice in
terms of the balance between inpatient and outpatient
care and the average length of inpatient stay. The mean
length of stay per person admitted to hospital varied
substantially between the trial centers from a mean of
47 (36) days in center 5, to a mean of 97 (45) days in
center 4.
The costs varied by location, whether a patient
was an inpatient at the time of entry into the trial
and whether inpatient care at baseline was an invol-
untary admission under the Mental Health Act or
not. These factors were statistically signiﬁcantly
correlated with each other as well as with costs
(P < 0.000). Descriptive analysis of the pooled data
suggests some possible reasons for the differences
between locations. First, locations 1 and 2 had fewer
patients that were inpatients at baseline (40% and
35%, respectively) than locations 3 and 4 (56% and
76%, respectively), which would suggest lower costs
in locations 1 and 2. Second, the majority of patients
in locations 1 (86%), 2 (93%), and 3 (73%) who
were admitted to hospital as inpatients (to initiate the
allocated therapy) were admitted under the informal
section of the Mental Health Act. In contrast, 35%
of patients in location 4 were admitted under the
informal section of the Mental Health Act and 20%
were formally detained. These differences would
suggest higher costs in location 4. Against this, 43%
of patients in location 4 were not admitted under the
Mental Health Act, which would suggest lower costs
for this location. The numbers of patients in each
treatment group are too low to compare clozapine
and other SGAs by location, involuntary hospital
admission, or whether the patient was an inpatient at
baseline.
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The increased costs in the clozapine group may
reﬂect the licensing requirement for inpatient admis-
sion to commence the drug. In 2002, the licensing
restriction in the United Kingdom for inpatient initia-
tion of clozapine was relaxed and some Trusts initiated
a daycase initiation policy for clozapine during the
course of the trial. At the time of ﬁrst dose, 84% of
participants allocated to the clozapine arm were inpa-
tients compared to 51% in the nonclozapine SGA
group. Nevertheless, the majority of participants ran-
domized to clozapine were inpatients before random-
ization (60%). A lower proportion of participants
randomized to other SGAs were inpatients before ran-
domization (40%). Approximately 17% of those in
the clozapine group were admitted to hospital on the
day of the ﬁrst dose or between randomization and the
day of the ﬁrst dose. The corresponding proportion for
those randomized to other SGAs was 3%. If inpatient
admission to initiate allocated drug treatment is
included as a covariate, then clozapine may be cost-
saving and the probability that clozapine is cost-
effective increases to 54% if decision-makers are
willing to pay £1 to gain a QALY.
The primary analysis used the published price of
Clozaril and Denzapine which accounts for approxi-
mately 75% of the market in England. However, the
probability that clozapine is cost-effective was not
increased substantially if the lower cost of Zaponex
were used in the analysis. This applied to both the
primary analysis and if the lower price of clozapine is
used and inpatient admission to initiate allocated drug
treatment is included as a covariate.
The picture painted by previous retrospective
cohort or case-controlled studies regarding savings on
inpatient days with clozapine may be limited to those
with chronic refractory disease and they have not been
supported by large prospective randomized and non-
randomized studies of effectiveness [15,40,71].
Few published economic studies compare clozapine
to other SGAs. Two published economic models con-
cluded that clozapine was both more costly and asso-
ciated with higher QALYs [13,14]. The level of costs
and relative difference in costs in both models was
lower than those observed here. The level of QALYs
was similar when adjusted to the same time frame of
1 year used in this trial. This economic analysis used
observed data to estimate QALYs and costs from a
pragmatic trial in the United Kingdom. In contrast, the
two modeling studies used conservative estimates of
the use and the costs of health service use. Inpatient
admissions and length of stay data for the models were
estimated from UK Hospital Episode Statistics, for all
people with schizophrenia and from a controlled trial
of day and inpatient therapy for people with acute
psychiatric illness. These sources may underestimate
the use of psychiatric hospital care by people with
schizophrenia. In addition, the use of other services in
the two modeling studies was based on minimum esti-
mates of the services required. A recent systematic
review of the relative costs of SGAs found that cloza-
pine was associated with equal or perhaps higher cost
than olanzapine and risperidone [51]. The authors of
the review noted several limitations with the studies
included. Effectiveness data were not reported in all
the studies, precluding quantitative analysis of cost-
effectiveness. Substantial heterogeneity in patient
groups, time horizon and study design, data analysis
and presentation precluded quantitative analysis of the
cost data. It was not possible to ascertain whether the
failure to ﬁnd differences in costs reﬂected no differ-
ence in costs or Type II errors due to lack of power.
This heterogeneity between articles meant that it was
not possible to formally combine the results of the
previous studies with this economic evaluation com-
paring clozapine to other SGAs.
Conclusion
In conclusion, this study adds to a limited body of
evidence to compare clozapine to other SGAs. It is the
ﬁrst economic and clinical RCT to compare clozapine
to other SGAs using a pragmatic trial design to reﬂect
policy and clinical choices in the UK NHS and the
lower cost of generic formulations of clozapine. The
results indicate that clozapine may be associated with
higher QALYs than SGAs, but at an additional cost.
The probability that clozapine is cost-effective reached
50% if decision-makers are willing to pay £33,000 to
gain 1 QALY. This means that if decision-makers are
prepared to pay less than £33,000 to gain 1 QALY,
other SGAs may be more likely to be cost-effective
than clozapine. If decision-makers are prepared to pay
more than £33,000 to gain 1 QALY, then clozapine
may be more likely to be cost-effective than other
SGAs. Clozapine may also be more likely to be cost-
effective if fewer patients have clozapine initiated as an
inpatient than found in this RCT. Analysis of policy-
and decision-making indicates that the NICE would
require additional reasons to accept an intervention as
effective and efﬁcient if it had cost-effectiveness ratios
with a high probability of being more than £35,000
[68]. The results and limitations of the analysis suggest
that there is still a need for further economic evalua-
tion of clozapine. There were indications that the loca-
tion of treatment, whether a patient was admitted
under the Mental Health Act and whether the patient
was an inpatient at recruitment into the study affected
costs. In addition, previous treatment and health status
at baseline appeared to inﬂuence both costs and
QALYs. The relative contribution of alternative SGAs,
including clozapine, and these other factors needs to
be explored in prospective observational studies to
inform policy and treatment choices.
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